Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annu...( ATLANTA Dec. 7 /- Ortho Biotech t...),Health

ATLANTA, Dec. 7 /PRNewswire/ -- Ortho Biotech today announced that 12 clinical studies of DOXIL(R) (doxorubicin HCl pegylated liposome injection) will be presented at the 49th annual meeting of the American Society of Hematology (ASH) at the Georgia World Congress Center on December 8-11, 2007.

"We are very pleased that ASH accepted these 12 studies for presentation," said Craig Tendler, M.D., Vice President, Medical Affairs, Oncology/Nephrology, Ortho Biotech Products, L.P. "These presentations are further evidence of Ortho Biotech's ongoing commitment to developing oncology therapeutics and to helping patients with cancer."
The 12 presentations include:

-- Phase I/II Study of Rituxan in Combination with DOXIL in Patients with

Relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without

Cardiac Toxicity - Myron S. Czuczman, Roswell Park Cancer Institute,

Buffalo, NY (Abstract 1369)

-- Saturday, December 8, 2007, 5:30 p.m.-7:30 p.m., Hall B3 and B4

(Poster Board #: 523-I)

-- Gene Expression Profiles (GEP) to Predict at Least Very Good Partial

Response to VELCADE, DOXIL, and Dexamethasone in Newly Diagnosed

Patients with Multiple Myeloma - Malathi Hari, University of Michigan,

Ann Arbor (Abstract 1489)

-- Sunday, December 9, 2007, 5:30 p.m.-7:30 p.m., Hall B3 and B4

(Poster Board #:643-I)

-- Pegylated Liposomal Doxorubicin in Combination with Bortezomib May

Provide Therapeutic Advantage for High-Risk Multiple Myeloma Patients

Relapsing within 12 Months of Stem Cell Transplant - Shaji Kumar, Mayo

Clinic, Rochester, MN (Abstract 2730)

-- Sunday, December 9, 2007, 6:00 p.m.-8:00 p.m., Hall B3 and B4

(Poster Board #:920-II)

-- Effect of Disease Stage and Time Since Diagnosis on Time to Progression

for Pegylated Liposomal Doxorubicin + Bortezomib vs. Bortezomib Al
'/>"/>